▁combination ▁with ▁len al id om ide ▁and ▁de x am eth as one ▁for ▁the ▁treatment ▁of ▁multiple ▁my el oma ▁in ▁adult s ▁after ▁at ▁least ▁one ▁prior ▁ther apy . ▁There ▁are ▁no ▁experiences ▁with ▁children ▁and ▁youth s ▁under ▁ 1 8 ▁years ▁of ▁age . ▁ ▁The ▁study ▁relevant ▁for ▁appro val ▁included ▁ 7 2 2 ▁people . ▁In ▁this ▁study , ▁i x az om ib ▁increased ▁the ▁median ▁time ▁of ▁pro gression - free ▁surv ival ▁from ▁ 1 4 . 7 ▁months ▁( in ▁the ▁place bo + len al id om ide + dex am eth as one ▁study ▁arm ▁including ▁ 3 6 2 ▁people ) ▁to ▁ 2 0 . 6 ▁months ▁( under ▁i x az om ib + len al id om ide + dex am eth as one , ▁ 3 6 0 ▁people ), ▁which ▁was ▁a ▁statist ically ▁significant ▁effect ▁( p ▁= ▁ 0 . 0 1 2 ). ▁ 1 1 . 7 % ▁of ▁patients ▁in ▁the ▁i x az om ib ▁group ▁had ▁a ▁complete ▁response ▁to ▁the ▁treatment , ▁versus ▁ 6 . 6 % ▁in ▁the ▁place bo ▁group . ▁Over all ▁response ▁rate ▁( complete ▁plus ▁partial ) ▁was ▁ 7 8 . 3 % ▁versus ▁ 7 1 . 5 %. ▁ ▁A ▁phase ▁ 3 ▁study ▁demonstrated ▁a ▁significant ▁improvement ▁in ▁pro gression - free ▁surv ival ▁( P FS ) ▁with ▁i x az om ib